Vanucizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Vanucizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Targetangiopoietin 2
Clinical data
SynonymsRG7221
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6529H10033N1733O2038S46
Molar mass146.6 kDa g·mol−1

Vanucizumab (RG7221) (INN) is an experimental humanized monoclonal antibody designed for the treatment of cancer.[1][2]

Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.

This drug was developed by Genentech/Roche.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.
  2. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).